Pharma BD Deal Intelligence
A bust: Pfizer paid ~$810M for Therachon's FGFR3 decoy TA-46, betting it could out-develop BioMarin's vosoritide, but the Phase 2 study was terminated in November 2022 for lack of efficacy at any dose, and Pfizer shelved the program entirely by January 2023.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Pfizer CSO Mikael Dolsten: 'By acquiring Therachon, we hope to leverage Pfizer's leading scientific and development capabilities to more rapidly advance this…
TA-46 is a recombinant FGFR3 decoy administered weekly subcutaneously; Pfizer to compete directly with BioMarin's vosoritide which has 'caught analysts' eyes'…
Phase 2 study of recifercept in children with achondroplasia. Overall status: TERMINATED. Why stopped: 'The study was terminated due to lack of efficacy at any…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Pfizer agreed to acquire Swiss clinical-stage biotech Therachon Holding AG for $340M upfront plus up to $470M in development milestones (~$810M total); announced 13-Feb-2019 and closed 1-Jul-2019. The lead asset, TA-46 (later named recifercept), is a soluble recombinant human FGFR3 decoy designed to sequester FGF ligands extracellularly and normalize overactive FGFR3 signaling in achondroplasia — a mechanism distinct from BioMarin's CNP-analog vosoritide (VOXZOGO). Pfizer divested Therachon's secondary FGF21 short-bowel-syndrome program back to the founders. The thesis ultimately did not pan out: Pfizer's Phase 2 study of recifercept in children (NCT04638153) was terminated on 18-Nov-2022 for lack of efficacy at all tested doses (not a safety concern), and Pfizer formally discontinued the recifercept achondroplasia program on 31-Jan-2023 amid a broader pipeline thinning — leaving BioMarin's VOXZOGO uncontested among approved achondroplasia therapies.
Assessment window: 5yr post-close.
Achondroplasia is the most common form of short-limbed skeletal dysplasia (dwarfism), caused in >95% of cases by a single G1138A point mutation in the FGFR3 gene that produces constitutively active receptor signaling and impaired endochondral ossification. Beyond short stature, patients face serious cardiovascular, neurological (foramen magnum stenosis), and metabolic complications; over 80% of cases arise from spontaneous mutations to average-stature parents.
At deal close (May 2019), achondroplasia had no approved disease-modifying therapy. BioMarin's vosoritide (BMN 111), a CNP analog that inhibits intracellular FGFR3 signaling downstream, was the clear front-runner — Phase 3 enrolling, eventually FDA-approved as VOXZOGO in November 2021 for children ≥5 (label later expanded to under 5). QED Therapeutics/BridgeBio's infigratinib, an oral pan-FGFR small-molecule inhibitor, was in early development and later progressed to Phase 3. Ascendis Pharma's TransCon CNP (navepegritide) entered Phase 2 as a long-acting CNP. Pfizer's $340M upfront / $470M milestones / ~$810M total bet on Therachon's TA-46 was a Phase 1 soluble FGFR3 decoy receptor — a fundamentally different mechanism that sequesters FGF ligands extracellularly rather than blocking downstream signaling. Both Pfizer and BioMarin held FDA/EMA Orphan Drug Designations. Pfizer divested Therachon's secondary FGF21-based short-bowel-syndrome program back to Therachon's founders. Pfizer ultimately discontinued the TA-46 program in 2023 after Phase 2 readouts, leaving BioMarin's VOXZOGO uncontested in the approved-therapy space.
Pfizer's Phase 2 study of recifercept in children with achondroplasia (NCT04638153) was terminated on 18-Nov-2022 after an interim analysis showed it would not meet its primary endpoint — lack of efficacy at all tested doses; not a safety concern.
Pfizer formally discontinued development of recifercept (formerly Therachon's TA-46) for achondroplasia on 31-Jan-2023 amid a broader pipeline thinning, ending the lead asset acquired in the 2019 Therachon deal.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Therachon Holding AG (this deal) | 2019 | $810M | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2019 deals · Pfizer Inc. deals · Rare Disease deals